【国药现代:注射用头孢他啶通过仿制药一致性评价】国药现代公告,控股子公司国药集团致君(深圳)制药有限公司的注射用头孢他啶(0.5g)通过仿制药质量和疗效一致性评价。该药品适用于治疗敏感细菌所致的全身性重度感染、下呼吸道感染等,2023年全球制剂销售额为4.76亿美元,全国公立医疗机构销售额为19.21亿元。国药致君累计研发投入约641.54万元。通过评价将有利于产品市场拓展和销售。

金融界
15 Apr
国药现代公告,控股子公司国药集团致君(深圳)制药有限公司的注射用头孢他啶(0.5g)通过仿制药质量和疗效一致性评价。该药品适用于治疗敏感细菌所致的全身性重度感染、下呼吸道感染等,2023年全球制剂销售额为4.76亿美元,全国公立医疗机构销售额为19.21亿元。国药致君累计研发投入约641.54万元。通过评价将有利于产品市场拓展和销售。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10